IP Library › Granted Patent US 12,415,804
Granted Patent B2
US 12,415,804 · App. 19/002,520 · Granted Sep 16, 2025

Compounds for activating a serotonin receptor

Inventors: Samuel Banister (Sydney, AU); William Jorgensen (Sydney, AU); Jinlong Tan (Sydney, AU); Lachlan Whish (Sydney, AU)
Assignee: PSYLO PTY LTD
C07D471/04A61K31/437A61K31/4545A61K31/5377
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,804
App. No.
19/002,520
Granted
Sep 16, 2025
Kind
B2
Abstract

The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

Claims (75)

1. A compound, selected from:

Com-

pound

No.

Structure

S1

S2

S3

S4

S5

S6

S7

S8

S9

S11

S12

S13

S14

S15

S16

S17

S18

S19

S20

S21

S22

S23

S24

S25

S26

S27

S28

S30

S31

S32

S33

S34

S35

S36

S37

S38

S39

S40

S41

S42

S43

S44

S45

S46

S47

S48

S49

S50

S51

S56

S57

S58

S59

S60

S61

S62

S63

S64

S65

S66

S67

S68

S69

S70

S71

S72

S73

S74

S75

or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, or stereoisomer thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2025
From: BANISTER, SAMUEL; JORGENSEN, WILLIAM; TAN, JINLONG; WHISH, LACHLAN
To: PSYLO PTY LTD
Reel/Frame 071198/0833 →
Priority Claims (1)
AU 2023902053 · Jun 28, 2023 · national
Continuity (2)
Continuation PCTAU2024050706 · Jun 28, 2024
Related Publication 20250206739A1 · Jun 26, 2025
References Cited (37)
US 5364866A · Strupczewski et al. · 1994 [cited by applicant]
US 11000534B1 · Sippy · 2021 [cited by applicant]
US 20100029629A1 · Conticello et al. · 2010 [cited by applicant]
EP 0737685B1 · 2000 [cited by applicant]
EP 0870768B1 · 2002 [cited by applicant]
WO WO1995010513A1 · 1995 [cited by applicant]
WO 2008004117A1 · 2008 [cited by applicant]
WO WO2008003736A1 · 2008 [cited by applicant]
WO 2009102805A1 · 2009 [cited by applicant]
WO 2010011546A1 · 2010 [cited by applicant]
WO 2013063492A1 · 2013 [cited by applicant]
WO WO2018106907A1 · 2018 [cited by applicant]
WO WO2021041539A2 · 2021 [cited by applicant]
WO 2021076572A1 · 2021 [cited by applicant]
WO 2021155468A1 · 2021 [cited by applicant]
WO 2021155470A1 · 2021 [cited by applicant]
WO 2021168082A1 · 2021 [cited by applicant]
WO 2021179091A1 · 2021 [cited by applicant]
WO 2021226416A1 · 2021 [cited by applicant]
WO WO2022120181A1 · 2022 [cited by applicant]
WO 2023018864A1 · 2023 [cited by applicant]
WO WO2023115165A1 · 2023 [cited by applicant]
WO WO2024026359A1 · 2024 [cited by applicant]
WO WO2025000051A1 · 2025 [cited by examiner]
Berge et al.; “Pharmaceuticals Salts”; Journal of Pharmaceutical Sciences; vol. 66 No. 1; Jan. 1977; 19 pages. [cited by applicant]
Whelligan et al.; “Two-Step Synthesis of Aza- and Diazaindoles from Chloroamino-N-heterocycles Using Ethoxyvinylborolane”; The Journal of Organic Chemistry; vol. 75; 2010; p. 11-15. [cited by applicant]
CAS Registry No. 784079-60-3; dated Nov. 18, 2024; 1 page. [cited by applicant]
CAS Registry No. 1337205-20-5; dated Oct. 18, 2011; 1 page. [cited by applicant]
CAS Registry No. 2172589-79-4; dated Feb. 1, 2018; 1 page. [cited by applicant]
CAS Registry No. 2025497-87-2; dated Nov. 6, 2016; 1 page. [cited by applicant]
Blache et al.; “Application of the mercuric acetate-edetic acid oxidation method to the synthesis of 11-aza-1, 2, 3, 4, 5, 6, 7, 12b-octahydroindolo [2, 3-a] quinolizines”; Heterocycles; vol. 45 No. 1; 1997; p. 57-69. [cited by applicant]
Fukuya et al.; “Practical Synthesis of 7-Azaserotonin and 7-Azamelatonin”; Synlett; vol. 33; 2022; p. 2033-2037. [cited by applicant]
Bertaccini et al., The relative potency of 5-hydroxytryptamine like substances, Arch Int Pharmacodyn Ther., 133:138-56, 1961. [cited by applicant]
Communication pursuant to Rule 114(2) EPC, Third Party Observations Regarding European Application No. 22908927.1, mailed Mar. 21, 2025, 27 pages. [cited by applicant]
Klein et al., Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships, Journal of Pharmacology and Experim… [cited by applicant]
Pigini et al., Analogs with a 1,2-benzisoxazole nucleus of biologically active indole derivatives. IV. 5-Hydroxytryptamine isosteres, Eur J Med Chem, 10:33-6, 1975. [cited by applicant]
Rao et al., Synthesis and radioprotective activity of beta-(3-indazolyl)-ethylamine derivatives , Yao Xue Xue Bao 22 (6): 426-432, 1987. [cited by applicant]